Noninvasive Markers of Hepatic Steatosis and Fibrosis Following Integrase Strand-Transfer Inhibitor (INSTI) Initiation in Women With Human Immunodeficiency Virus (HIV)
- 3 February 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (2) , 304-313
Abstract
Background: The impact of integrase strand-transfer inhibitors (INSTIs) on steatotic liver disease in women with HIV (WWH) is unknown. Methods: Using data collected in the Women's Interagency HIV Study from 2007–2020, change in Fibrosis-4 index (FIB4), aspartate aminotransferase to platelet ratio index (APRI), and nonalcoholic fatty liver disease fibrosis score (NFS) over 5 years was compared between virologically suppressed WWH who switched to or added an INSTI to their antiretroviral therapy (ART) and WWH remaining on non-INSTI ART. In participants with transient elastography (TE) measures, estimates of hepatic steatosis (controlled attenuation parameter [CAP]), fibrosis (liver stiffness [LS]), and steatohepatitis (FibroScan-aspartate aminotransferase [FAST] scores) were compared by group. Results: A total of 872 WWH (323 INSTI, 549 non-INSTI) were included, and 280 (146 INSTI, 134 non-INSTI) had TE. Of these, 61% were non-Hispanic Black; mean age was 47 years and body mass index was 31.4 kg/m2. Among non-obese women, those in the INSTI versus non-INSTI group had a greater increase in NFS (but not FIB4 or APRI) over time (study group × time, P = .015). Those in the INSTI versus non-INSTI group also had greater CAP (+25; 95% CI: .28–49; P = .048), LS (+1.23; 1.01–1.49; P = .038), and FAST scores (+1.97; 1.17–3.31; P = .011) and a 3.7 (1.2–11.4; P = .021) greater odds of having hepatic steatosis (CAP ≥248 dB/m) within 1 year of starting an INSTI. Conclusions: Hepatic steatosis risk was increased only within the first year following INSTI initiation among WWH. Longitudinal hepatic assessments are warranted to evaluate whether these changes are associated with clinically significant liver disease.Keywords
Funding Information
- National Institutes of Health
This publication has 35 references indexed in Scilit:
- Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2023
- Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesityInternational Journal of Obesity, 2021
- Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency VirusClinical Gastroenterology and Hepatology, 2020
- NASH in HIVCurrent HIV/AIDS Reports, 2020
- Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and CanadaJournal of the International AIDS Society, 2020
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation studyThe Lancet Gastroenterology & Hepatology, 2020
- American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver DiseasesGastroenterology, 2017
- Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosisJournal of Hepatology, 2017
- Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2009
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003